Castle Biosciences, Inc. has revealed plans to disclose its financial results for the second quarter ending June 30, 2026, following the close of U.S. market trading on Thursday, July 30, 2026. The company's leadership will host a live webcast at 4:30 p.m. Eastern Time on that same day to review the financial performance and discuss business developments.

Interested parties can access the webcast via the company's investor relations website. It is recommended that participants log in at least 10 minutes prior to the scheduled start time. A replay of the webcast will be made available for on-demand viewing after the live event concludes.

Castle Biosciences, headquartered in Friendswood, Texas, is a precision diagnostics company focused on dermatological and gastrointestinal conditions. Its mission is to guide patient care through innovative testing. The company currently has six commercialized test offerings. Its primary products include the DecisionDx suite of tests for managing melanoma and squamous cell carcinoma, the TissueCypher test for assessing the risk of progression in Barrett's esophagus, and the IDgenetix test for guiding pharmacotherapy in mental health conditions.

Based on the company's first-quarter financial report, revenue reached $83.7 million, with the volume of core test reports increasing by 36% year-over-year. The DecisionDx-Melanoma and TissueCypher tests were highlighted as particularly strong performers. The company has subsequently raised its full-year 2026 revenue guidance to a range of $345 million to $355 million. Analysts are forecasting a second-quarter loss per share of approximately $0.40.

Key Areas of Market Focus

Market observers are paying close attention to several key areas. These include the sustainability of growth for the core test portfolio, the expansion progress of the TissueCypher test, and the commercialization efforts and progress in securing insurance coverage for the new product, AdvanceAD-Tx, which is designed for atopic dermatitis.